Phosphatase
Phosphatases are enzyme that remove a phosphate group from a protein. Protein tyrosine phosphatases (PTPs) comprise a diverse family of transmembrane and cytoplasmic enzymes. PTPs play an important role in regulating the proliferative activity of cells and the integrity of cell-cell and cell-matrix contacts. Protein tyrosine phosphatase 1B (PTP1B) is a non-receptor PTP frequently associated with the endoplasmic reticulum and vesicles subjacent to the plasma membrane. PTP1B as a key negative regulator of leptin receptor pathways has been an attractive therapeutic target for the treatment of type 2 diabetes mellitus and obesity. Four major serine/threonine-specific protein phosphatase catalytic subunits are present in the cytoplasm of animal cells. Three of these enzymes, PP1, PP2A, and PP2B, are members of the same gene family, while PP2C appears to be distinct.The alkaline phosphatases comprise a heterogeneous group of enzymes that are widely distributed in mammalian cells. Acid phosphatase enzymes catalyze the hydrolysis of phosphate monoesters following the general equation.
All Product Categories
-
Phosphatase Inhibitors
(514)
View all products
-
Phosphatase Agonists
(4)
View all products
-
Phosphatase Antagonists
(4)
View all products
-
Phosphatase Activators
(79)
View all products
-
Phosphatase Modulators
(7)
View all products
-
Phosphatase Chemical
(1)
View all products
-
Phosphatase Inducers
(2)
View all products
-
Phosphatase Degraders
(7)
View all products
-
Phosphatase Controls
(3)
View all products
-
Phosphatase Substrates
(4)
View all products
-
Phosphatase Ligands
(11)
View all products
-
Phosphatase Proteins
(66)
View all products
-
Phosphatase Related Products (729)
Related Products (729)
-
Recombinant Proteins (66)
-
Antibodies (40)
-
Related Compound Screening Libraries (1)
-
NFh-ALP
0 ImagesCat. No.: HY-159485NFh-ALP is an alkaline phosphatase (ALP)-activatable photosensitizer. NFh-ALP could be activated by ALP in cells and generate 1O2 under 808 nm excitation, effectively killing tumor cells by inducing apoptosis and having good biocompatibility. The maximum absorption wavelength of NFh-ALP is about 656 nm.
-
L-690488
0 ImagesCat. No.: HY-101076CAS No.: 142523-14-6L-690488 is a proagent of L-690330 and is a selective inositol monophosphatase (IMPase) inhibitor. L-690488 has more effective cell penetration than L-690330.
-
SHP2 inhibitor LY6
0 ImagesCat. No.: HY-125257CAS No.: 2296718-09-5Synonyms: LY6SHP2 inhibitor LY6 (LY6) is a selective SHP2 inhibitor with an IC50 of 9.8 μM, showing 7-fold selectivity over SHP1. SHP2 inhibitor LY6 inhibits SHP2-mediated cell signaling pathways and suppresses cell proliferation. SHP2 inhibitor LY6 elicits induces apoptosis and G2/M cell cycle arrest in lung cancer cells. SHP2 inhibitor LY6 can be used for the research of B cell acute lymphoblastic leukemia, acute myeloid leukemia, and lung cancer.
-
SHIP1 activator 1
0 ImagesCat. No.: HY-113817CAS No.: 1000010-33-2SHIP1 activator 1 is an SH3 domain-containing inositol 5-phosphatase regulator with SHIP1 activating activity. SHIP1 activator 1 retains its SHIA-1 activating ability by removing unnecessary functional groups. SHIP1 activator 1 is able to activate SHIP1 in vitro, inhibit Akt phosphorylation in MOLT-4 cells, and show dose-dependent activity in a mouse model of inflammation. SHIP1 activator 1 is an important chemical tool for evaluating the potential of SHIP1 activators as inhibitors of hematopoietic diseases involving abnormal PI3K cell signaling.
-
PTP1B-IN-26
0 ImagesCat. No.: HY-162479PTP1B-IN-26 (Compound 7a) is a derivative of phenylthiosemicarbazide‐phenoxy‐1,2,3‐triazole‐N‐phenylacetamide. PTP1B-IN-26 is an inhibitor of protein tyrosine phosphatase 1B (PTP-1B). PTP1B-IN-26 is a competitive inhibitor. PTP1B-IN-26 can be used to research in type 2 diabetes.
-
PTP1B-IN-29
0 ImagesCat. No.: HY-170582PTP1B-IN-29 (Compound A2B5) is an inhibitor for phosphatase, that inhibits protein tyrosine phosphatase 1B (PTP1B), TCPTP and λPPase with IC50s of 1.27 μM, 4.38 μM and 8.79 μM, respectively. PTP1B-IN-29 can be used in research of diabete and obesity.
-
RB-CO-PEG5-C2-CO-VH032
0 ImagesCat. No.: HY-161393RB-CO-PEG5-C2-CO-VH032 is a VHL-recruiting TRIM24 PROTAC degrader composed of an RB-derived short peptide SPRT, a PEG5-C2 linker, and the VHL ligand VH032. RB-CO-PEG5-C2-CO-VH032 recognizes proteins containing the FXXXV motif and recruits VHL to induce degradation of proteins such as TRIM24, thereby upregulating DUSP2, inhibiting ERK/mTOR signaling, and suppressing prostate cancer cell proliferation. RB-CO-PEG5-C2-CO-VH032 can be used for TRIM24 degradation and prostate cancer-related research.
-
Naphthol AS-GR phosphate disodium
0 ImagesCat. No.: HY-D1520CAS No.: 100929-51-9Naphthol AS-GR phosphate disodium is substrates for acid and alkaline phosphatases. Naphthol AS-GR phosphate disodium has an intense green fluorescence used in histochemical studies.
-
Albafuran A
0 ImagesCat. No.: HY-N17455CAS No.: 84323-14-8Albafuran A (Compound 1/4) is a protein tyrosine phosphatase 1B (PTP1B) inhibitor and can be used in research related to type 2 diabetes and obesity.
-
Cyanidin 3-arabinoside
0 ImagesCat. No.: HY-N4143CAS No.: 27214-72-8Cyanidin 3-arabinoside is a selective and reversible protein tyrosine phosphatase 1B (PTP1B) inhibitor, with an IC50 of 8.91 μM. Cyanidin 3-arabinoside is potential for the research of type 2 diabetes.
-
CDC25-IN-2
0 ImagesCat. No.: HY-28086CAS No.: 116452-88-1CDC25-IN-2 (Compound 1d) is a selective phosphatase Cdc25 inhibitor with IC50 values of 44.4, 55.2 and 53.9 μM for human Cdc25A, Cdc25B, Cdc25C. CDC25-IN-2 can block the cell cycle progression by inhibiting the activity of Cdc25 phosphatase. CDC25-IN-2 can be used for the research of cancer.
-
S-3483
0 ImagesCat. No.: HY-16442CAS No.: 160341-09-3S-3483, a Chlorogenic acid (HY-N0055) derivative, is a reversible, linear competitive glucose-6-phosphatase (Glc-6-Pase) system inhibitor. S-3483 inhibits Glc-6-Pase with a Ki 129 nM in rat liver microsomes. S-3483 specifically inhibits Glc-6-P transporter of renal and liver microsomes.
-
NSC 295642
0 ImagesCat. No.: HY-152168CAS No.: 77111-29-6NSC 295642 is a phosphatase inhibitor. NSC 295642 can significantly increase phospho-Erk cytonuclear differences in intact cells. NSC 295642 can be used for the research of cancer.
-
PTPN22-IN-3
0 ImagesCat. No.: HY-184931PTPN22-IN-3 is a potent, selective, and orally active inhibitor of PTPN22 with an IC50 of 0.49 μM and a Ki of 0.28 μM. PTPN22-IN-3 exhibits over 14-fold selectivity against a broad panel of PTPs and shows no significant inhibition against SRC/CSK kinases or IDO1/Arginase metalloenzymes. PTPN22-IN-3 enhances TCR signaling, increases IL-2 expression and secretion, and promotes mouse splenic T cell proliferation. In immune-competent C57BL/6J mice, PTPN22-IN-3 suppresses MC38 syngeneic tumor growth and synergizes with Pembrolizumab (anti-PD-1) (HY-P9902A) therapy. PTPN22-IN-3 can be used for the study of colorectal cancer and other solid tumors responsive to T cell-mediated anti-tumor immunity.
-
Sambucus adnata extract
0 ImagesCat. No.: HY-N20416Sambucus adnata extract is an extract of Sambucus adnata that has significant protein tyrosine phosphatase 1B (PTP1B) inhibitory activity.
-
NCGC00063279
0 ImagesCat. No.: HY-182634CAS No.: 714932-54-4NCGC00063279 is a reversible Werner Syndrome Helicase-Nuclease (WRN) helicase inhibitor with modest selectivity over BLM and FANCJ helicases, and does not inhibit WRN exonuclease activity at active concentrations. NCGC00063279 inhibits Hematopoietic Protein Tyrosine Phosphatase (HePTP) and reduces proliferation of cancer cells. NCGC00063279 can be used for the research of osteosarcoma.
-
RP04340
0 ImagesCat. No.: HY-189222CAS No.: 3118096-98-0RP04340 is an orally active, selective pan-KRAS PROTAC degrader. RP04340 hijacks the CRBN E3 ligase and the cellular proteasome system to degrade KRAS, without degrading HRAS, NRAS, or common CRBN neosubstrates. RP04340 inhibits KRAS downstream signaling pathways, including pERK and DUSP6. RP04340 exhibits anticancer activity in various KRAS-mutant cancers. RP04340 can be used to study kras-driven cancers, including pancreatic ductal adenocarcinoma, colorectal cancer, and lung adenocarcinoma.
